Douglas Gladue | Vice President Veterinary Pharmaceutical Development
Seek Labs

Dr. Douglas Gladue currently is an internationally recognized leader in bringing projects from concept to commercialization, with over 20 years of experience leading diverse research teams. As the Vice President for Veterinary Pharmaceutical Development at Seek Labs he leads a team to develop new CRISPR based therapeutics to cure viral diseases in animals, and has successfully developed the first therapeutic that targets African swine fever virus (ASFV) by destroying the viral DNA, the host response is able to clear ASFV and fully recover. Prior to joining Seek labs, Dr. Gladue ran a remote team of Computational Biologists and a Wet lab team for the United States Department of Agriculture (USDA) at Plum Island Animal Disease Center, a biosafety level 3 facility focusing in Foreign Animal Diseases. He is the inventor of the first and second commercially produced live-attenuated vaccines for African Swine Fever (ASF). Dr. Gladue was awarded the prestigious Arthur S. Flemming award for his accomplishments in revolutionizing the field of ASF, inventing vaccine platforms, developing new diagnostic tools, recharacterizing ASF virus isolates and developing an automated computational pipeline for sequencing the large DNA genome of ASF virus.  Dr. Gladue has served in several elected positions and is currently the Scientific Director for the global African Swine fever Alliance (GARA) and the director of the Center of Excellence for ASFV genomics, and previously was elected the Treasurer for the World society of virology (WSV). Dr. Gladue regularly serves on multiple scientific committees, grant review panels, and academic program review committees. He has authored over 100 peer-reviewed scientific publications, as serves as editor for several scientific journals.